Stockscreener 앱 받기
35.54
0.89%
-0.32
시장 영업 전:
35.65
0.11
+0.31%
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
STOK: Zorevunersen shows sustained efficacy and cognitive gains, with phase III readout expected mid-2027 - TradingView — Track All Markets
Price-Driven Insight from (STOK) for Rule-Based Strategy - Stock Traders Daily
Baillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Fed Meeting: Is Stoke Therapeutics Inc a strong candidate for buy and hold2026 Bull vs Bear & Weekly Market Pulse Alerts - baoquankhu1.vn
Treasury Yields: Is Stoke Therapeutics Inc a cyclical or defensive stock2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
STOK Should I Buy - Intellectia AI
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - NTB Kommunikasjon
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Stoke Therapeutics Appoints Clare Kahn, Ph.D. to Board and Advances Zorevunersen for Dravet Syndrome Treatment - Minichart
Stoke Therapeutics appoints Clare Kahn to board of directors By Investing.com - Investing.com Australia
Stoke Therapeutics Appoints Clare Kahn to Board - citybiz
Stoke Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Stoke Therapeutics (STOK) director receives 30,782-share stock option grant - Stock Titan
Stoke Therapeutics (STOK) director Kahn Clare submits initial Form 3 insider report - Stock Titan
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight - TipRanks
Stoke Therapeutics appoints Clare Kahn to board of directors - Investing.com
Clare Kahn joins Stoke Therapeutics (Nasdaq: STOK) board, receives option grant - Stock Titan
Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026 - marketscreener.com
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors - Yahoo Finance
Trading Recap: Can Stoke Therapeutics Inc grow without external fundingQuarterly Market Summary & Technical Entry and Exit Tips - baoquankhu1.vn
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus - Yahoo Finance
Growth Value: What is the earnings history of Stoke Therapeutics Inc2026 Major Catalysts & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 1,838 shares in planned open-market trade - Stock Titan
(STOK) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79 - MSN
Insider sells shares under 10b5-1 — STOK (NASDAQ: STOK) discloses trades - Stock Titan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stoke Therapeutics (STOK) price target increased by 12.11% to 43.96 - MSN
Stoke Therapeutics Hits Day High with 7.98% Surge in Strong Intraday Performance - Markets Mojo
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares - AOL.com
Stoke Therapeutics, Inc. Files 8-K Announcing Change in Certifying Accountant – March 2026 - minichart.com.sg
Stoke Therapeutics (NASDAQ: STOK) replaces KPMG with EY as auditor - stocktitan.net
Vanguard reports zero Stoke Therapeutics holdings (STOK) - stocktitan.net
Big Money Moves: What hedge funds are buying Stoke Therapeutics Inc2026 Update & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Whale Trades: What is the earnings history of Stoke Therapeutics IncAnalyst Upgrade & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Gains Recap: How does Stoke Therapeutics Inc score in quality rankings2026 Historical Comparison & Expert Curated Trade Setups - baoquankhu1.vn
Allan Jonathan, Stoke Therapeutics general counsel, sells $313k in STOK stock - Investing.com Canada
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally - AOL.com
Stoke Therapeutics Insider Sold Shares Worth $313,038, According to a Recent SEC Filing - MarketScreener
Stoke Therapeutics (STOK) counsel sells 9,293 shares under 10b5-1 plan - Stock Titan
FY2030 Earnings Estimate for STOK Issued By HC Wainwright - MarketBeat
(STOK) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Stoke earnings loom as analysts bet big on Dravet therapy potential By Investing.com - Investing.com Australia
Stoke earnings loom as analysts bet big on Dravet therapy potential - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Lowered by Wall Street Zen - MarketBeat
Form 144 STOKE THERAPEUTICS INC For: 20 March By Investing.com - Investing.com Canada
Form 144 STOKE THERAPEUTICS INC For: 20 March - Investing.com
Canaccord Genuity Group Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
2.69%
0.25%
자본화:
|
볼륨(24시간):